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Abstract: In the present work, we demonstrate the preparation of chitosan-based composites as
vehicles of the natural occurring multi-drug resveratrol (RES). Such systems are endowed with
potential therapeutic effects on inflammatory bowel diseases (IBD), such as Crohn’s disease (CD)
and ulcerative colitis, through the sustained colonic release of RES from long-lasting mucoadhesive
drug depots. The loading of RES into nanoparticles (NPs) was optimized regarding two independent
variables: RES/polymer ratio, and temperature. Twenty experiments were carried out and a
Box–Behnken experimental design was used to evaluate the significance of these independent
variables related to encapsulation efficiency (EE). The enhanced RES EE values were achieved in
24 h at 39 ◦C and at RES/polymer ratio of 0.75:1 w/w. Sizes and polydispersities of the optimized
NPs were studied by dynamic light scattering (DLS). Chitosan (CTS) dispersions containing the
RES-loaded NPs were ionically gelled with tricarballylic acid to yield CTS-NPs composites. Macro-
and microscopic features (morphology and porosity studied by SEM and spreadability), thermal
stability (studied by TGA), and release kinetics of the RES-loaded CTS-NPs were investigated. Release
patterns in simulated colon conditions for 48 h displayed significant differences between the NPs
(final cumulative drug release: 79–81%), and the CTS-NPs composites (29–34%).
Keywords: colon; inflammatory bowel disease; IBD; drug depot; mucoadhesive; Crohn’s disease;
ulcerative colitis; nanoparticles; hydrogels
1. Introduction
Although inflammation is part of the normal host response to infection and injury, excessive or
inappropriate inflammation contributes to a range of acute and chronic human diseases which are
characterized by the production of inflammatory cytokines, arachidonic acid–derived eicosanoids,
other inflammatory agents and adhesion molecules [1]. Thus, high concentrations of Tumor
necrosis factor (TNF-α), Interleukin-12 (IL-12), and Interleukin-6 (IL-6) are particularly destructive
and are implicated in some of the pathologic responses that occur in endotoxic shock, in acute
respiratory distress syndrome, and in chronic inflammatory diseases such as rheumatoid arthritis and
inflammatory bowel disease (IBD) [2].
IBD is a group of disorders characterized by a chronic and relapsing inflammation of the
gastrointestinal tract frequent in Western countries [3]. The two most common forms of IBD are Crohn’s
disease (CD) and ulcerative colitis (UC). They lead to long-term and sometimes irreversible impairment
of gastro-intestinal structure and function [4]. In UC, a diffuse mucosal inflammation of the colon is
mainly found as well as the coincident production of a complex mixture of inflammatory mediators
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and extensive superficial mucosal ulceration. Conversely, in CD, any part of the gastro-intestinal tract
(GIT) from the mouth to the anus can be affected, although it is usually the ileum and colon. Unlike
UC, CD may be patchy and segmental. In addition, inflammation can be typically transmural [1,2].
It has been hypothesized that IBD results from an inappropriate and exaggerated mucosal immune
response to normal constituents of the mucosal microflora that is, in part, genetically determined [2].
It is now well established that microbial components of the resident microbiota can regulate gut
inflammation [5]. In CD, in particular, the intestinal microbiota is strongly suspected to play a role in
initiating and triggering the immune system, leading to characteristic inflammation [6,7]. However,
the inheritable component also plays a role and seems stronger in CD than in ulcerative colitis [8].
Moreover, it is worth highlighting that in several countries with historically low rates of IBD, a pattern
of rising incidence in the past one to two decades, particularly for CD, has occurred, suggesting that
environmental factors are also involved [4].
IBD has an enormous impact on people’s lives. According to the Institute for Health Metrics
and Evaluation (GBD 2017, University of Washington) IBD was responsible, globally, for the 0.07% of
deaths that occurred in the world in 2017, i.e., the death of 3.86 million people was directly correlated
with some of these pathologies. However, they also have a marked influence on the quality of life of ill
people. Thus, the global disability-adjusted life years (DALYs) connected with these disorders was
of 184.95 million in 2017. The highest DALY values were found for people from England, the United
States of America and Norway, as can be seen in Figure 1. Therefore, finding new therapies aimed at
the overall reduction of the incidence of IBD is a necessity.
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Conventional treatment of IBD is based on the daily administration of high doses of immune-
suppressant or anti-inflammatory drugs, often complicated by serious adverse effects. Thus, a carrier
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system that delivers the drug specifically to the inflamed intestinal regions and shows prolonged drug
release would be desirable [9].
Resveratrol (RES), a natural occurring polyphenol, is the main biologically active component in
red wine. Hundreds of publications have demonstrated that RES can prevent or delay the progression
of a wide variety of diseases [10] due to its antiplatelet activity [11] as well as antitumor [12],
neuroprotective [13,14] and anti-inflammatory [15,16] properties. Resveratrol has been reported
to decrease inflammation by inhibiting the induced production of pro-inflammatory cytokines, such as
TNF-α, IL-1β, IL-6, and IL-8, and matrix metalloproteinases MMP-2, MMP-3, MMP-9 and MMP-13,
in in vitro and in vivo models [17]. The main problem associated with the therapeutic use of RES is
its rapid metabolism in vivo [18] and it is related to its low water solubility and chemical instability.
This drawback has been addressed by the preparation of resveratrol derivatives so that their intrinsic
biological activity and bioavailability would be improved [17,19,20].
The development of colon-targeting drug delivery systems (DDS) is one of the most grown fields
in pharmaceutical technology. They can be employed for both local-acting drugs and active principles
intended for systemic absorption. These colon specific drug delivery systems are gaining importance
for use in the treatment of colon cancer, chronic disorders, such as IBD and also for the systemic delivery
of protein and peptide drugs. Ferris et al. reported the preparation of reduction-sensitive biodegradable
multiallyl- and multiamine-based copolyurethanes for their use as colon-targeted anticancer drug
carriers [21]. Xu et al. [22] prepared dual crosslinked gel beads composed of alginate and chitosan
for the colonic site-specific delivery of bovine serum albumin [23]. Peppas and colleagues have
reported the preparation of responsive hydrogels for the treatment of the irritable bowel syndrome [24].
Hydrogel patches that contain nanoparticles (NPs) loaded with siRNA and a chemo drug were
capable of preventing the recurrence of colon cancer in a murine model [25]. Dextran-based hydrogels
have been investigated as colon-targeted drug delivery systems due to the presence of dextranase
in the colon [26]. Resveratrol formulations of Zn-pectin-chitosan microparticles have demonstrated
colon-specific drug release [27]. The use of micro-nanoparticles (MNP) in therapy of IBD with enhanced
colonic retention of drugs has been reported [28].
In the current paper and based on our previous experience, we aim at the preparation of
nanostructured chitosan-based hydrogels as a vehicle for RES in order to improve its ADME-T
properties (absorption, distribution, metabolism, excretion and toxicity) for its final use in IBD.
RES will be encapsulated into recently designed biocompatible non- and cross-linked poly(2-
hydroxyethyl methacrylate)-based NPs as controlled DDS [29]. They have already demonstrated
its capability of solubilizing lipophilic molecules such as pyrene, pilocarpine and the anticancer drug
camptothecin [29–32]. The optimization conditions for loading RES into the NPs will be determined.
The RES-loaded NPs will then be embedded into a shear-thinning chitosan-based hydrogel to form
micro- and nano-structured smart hydrogel composites with bioadhesion properties as a drug depot.
The release studies of RES will be conducted in simulated colonic fluids from both the NP systems and
the hydrogel nanocomposites.
2. Results and Discussion
In general terms, polymeric DDSs enhance the solubility of scarcely soluble drugs, improving their
biodistribution and pharmacokinetics, and minimizing the side effects of the therapeutic molecules
under study [33]. In the current work, the therapeutic molecule RES has been loaded into amphiphilic
NPs that have demonstrated a highly efficient encapsulation efficiency for other lipophilic drugs such
as pyrene, pilocarpine and camptothecin [29–32]. The hydrophilicity of the shells ensures the stability
of the NPs in aqueous media. In the present work, the hydrophilic layer of the NPs is constituted by
the biocompatible and widely used poly(2-hydroxyethyl methacrylate) (pHEMA) and the pH sensitive
poly(N,N-dimethylaminoethyl methacrylate) (pDMAEMA). pHEMA is a non-toxic and biocompatible
hydrophilic material and it is particularly attractive for biomedical engineering applications [34] as
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well as pDMAEMA, polymer used in the co-delivery of paclitaxel and DNA [35] with pH responsive
behavior [36].
It was been stated that the instability associated to the micelle-unimers equilibrium by dilution
in human fluids could lead to premature drug release in off-targeted tissues [37]. In order to study
the influence of dilution on the prepared RES-loaded NPs, a double study has been conducted with
non-stabilized NPs and with a batch of cross-linked, hence, stabilized NPs [29].
2.1. Resveratrol-Loaded Nanoparticules
To optimize the loading of RES into the freshly prepared NPs, the variables investigated were those
that displayed the most marked effect on the encapsulation efficiency (EE) of the drug camptothecin
by these systems [32], i.e., drug/polymer ratio, and temperature.
The notable influence of drug/polymer ratios in the feed on the EE of hydrophobic molecules
into polymer NPs has been confirmed in multiple studies. In general terms, it has been observed that
the bigger the drug concentration in the feed, the higher was its EE [34,38–41]. For the experimental
design, RES-polymer ratios were set to values of 0.25, 0.50 and 0.75 (w/w). The range of temperature
chosen for the current experimental design (from 25 ◦C to 39 ◦C) was selected based on the most
common laboratory working temperature (25 ◦C) and with the objective of keeping the hydrophilicity
of the shells, i.e., avoiding them reaching the lower critical solution temperature (LCST) of pDMAEMA
(42 ◦C [42]), the main component of NP shells.
Table 1 shows the values of the independent variables and the experimental values of the EE
obtained for both the non- and the cross-linked NPs.
Table 1. Experimental encapsulation efficiency values of resveratrol loaded NPs (nanoparticles)
for non-cross-linked and cross-linked systems at different RES (Resveratrol)/polymer ratios and
temperatures following the experimental design 1.
Experimental Parameters Non Cross-Linked Loaded NPs
RES/Polymer Ratio Temperature (◦C) Sample Formulation Code EE (%)
0.25 25 1 NonXr-RES/Pol0.25-T25 6.80
0.25 25 2 NonXr-RES/Pol0.25-T32 29.51
0.25 25 3 NonXr-RES/Pol0.25-T39 33.82
0.50 32 4 NonXr-RES/Pol0.5-T25 23.87
0.50 32 5 NonXr-RES/Pol0.5-T32 36.00
0.50 32 6 NonXr-RES/Pol0.5-T32 38.18
0.50 32 7 NonXr-RES/Pol0.5-T39 49.37
0.75 39 8 NonXr-RES/Pol0.75-T25 18.31
0.75 39 9 NonXr-RES/Pol0.75-T32 37.54
0.75 39 10 NonXr-RES/Pol0.75-T39 48.10
Experimental Parameters Cross-Linked Loaded NPs
RES/Polymer Ratio Temperature (◦C) Sample Formulation Code EE (%)
0.25 25 11 Xr-RES/Pol0.25-T25 9.51
0.25 25 12 Xr-RES/Pol0.25-T32 43.74
0.25 25 13 Xr-RES/Pol0.25-T39 49.01
0.50 32 14 Xr-RES/Pol0.5-T25 12.57
0.50 32 15 Xr-RES/Pol0.5-T32 38.00
0.50 32 16 Xr-RES/Pol0.5-T32 40.09
0.50 32 17 Xr-RES/Pol0.5-T39 36.19
0.75 39 18 Xr-RES/Pol0.75-T25 28.46
0.75 39 19 Xr-RES/Pol0.75-T32 43.12
0.75 39 20 Xr-RES/Pol0.75-T39 44.34
1 Each value is the average of three samples (p < 0.05). EE = encapsulation efficiency; RES/polymer ratio: 0.25, 0.5
or 0.75; Temperature: 25, 32 or 39 ◦C.
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In Table 2, the obtained equations calculated using polynomial regression and statistics parameters
are shown.
Table 2. Equations yielded for the dependent variable (EE) as a function of the independent variables
(RES/polymer ratio and temperature, normalized values) for the experimental design.
Equation R2 Df F P Std. Error
XrEE = 37.88 + 13.17 T − 12.34 T2 + 6.71 C2 − 5.90 T C 0.96 4.5 29.03 0.001 3.69
NonXrEE = 38.89 + 13.72 T − 4.07 T2 + 5.64 C− 7.17 C2 0.97 4.5 49.96 0.003 2.74
C = RES/polymer ratio normalized value; C = RES/polymer ratio normalized value; XrEE = encapsulation efficiency
in percentage for core cross-linked NPs; NonXrEE = encapsulation efficiency in percentage for non-cross-linked NPs
The obtained equations show acceptable (> 0.96) R2, (> 25) F and (> 0.005) p-values, the reason
why a suitable modelling is proved. However, in both equations, complex terms involving interactions
between independent variables have been calculated.
Moreover, identifying the independent variables most and least strongly influencing the
dependent variables in equations showed in Table 2 is not straightforward since those equations
contain interactions between two independent variables terms. A Pareto chart, also called a Pareto
distribution diagram, is used for analyzing what independent variables (p > 0.05) have the greatest
cumulative effect on this study. Figure 1 shows a plot of each dependent variable (compound) and its
Pareto chart of standardized effects (as percentages) based on independent variables.
The Pareto charts (Figure 2) show that the most important variable on non-cross-linked EE
evolution is temperature (83%); it happens, likewise, on camptothecin loaded NPs [32]. However,
similar relative statistical influence (48% and 52% for temperature and drug/polymer ratio respectively)
has been found for 20% cross-linked treatment. In general terms, as observed previously for other
systems, the higher the drug/polymer ratio, the greater the EE. The EE values are also in agreement
with those obtained for camptothecin at similar drug/polymer ratios. To help the interpretation of the
obtained equations, the response surface for each dependent variable is shown (Figure 3).
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Figure 3. Response surface for RES encapsulation efficiency percentage on both, non- and
cross-linked NPs.
The RES-loaded NPs with optimized EE (Table 3) were studied by DLS. The Z-average and Dh of
the non-cross-linked system experienced a slight reduction compared to the unloaded counterpart.
This could be due to the pi–pi tacking of the drug molecules and the furfuryl rings of the core of the
NP, causing more compact micelles. In the case of cross-linked NP loaded with RES, the size became
slightly higher than the unloaded corresponding NP, as has been observed for other systems [31,32].
Table 3. Comparison of Z-average, polydispersity index (PdI), and hydrodynamic diameter (Dh,
determined by DLS) of non-cross-linked NP (Non-Xr) and stabilized NP at 20% of cross-linking (Xr)
(unloaded or loaded with RES).
Unloaded Samples [31] Resveratrol-Loaded NPs
Degree of
Crosslinking Sample
Z-av (± SD)
PdI (± SD) Size (± SD)(Dh. nm) Sample
Z-av (± SD)
PdI (± SD) Size (± SD)(Dh. nm)(nm) (nm)
Non-Xr S-01 177 (± 1) 0.14 (± 0.02) 210 (± 80) RES-Non-Xr 115 (± 1) 0.46 (± 0.01) 170 (± 90)
Xr 20% S-02 108 (± 1) 0.33 (± 0.01) 130 (± 70) RES-Xr 121 (± 1) 0.27 (± 0.01) 170 (± 90)
The RES-loaded NPs were prepared at pH 7.0 according to the optimized conditions found in the present study:
Sample RES-Non-Xr = Non-Xr-Res0.75-T39; RES-Xr = Xr-Res0.75-T39; Temperature = 39 ◦C; RES/polymer ratio =
0.75:1; loading time = 24 h.
2.2. Nanostructured Chitosan-Based Composites Containing Resveratrol-Loade NPs
Hydrogels are currently being studied as matrices for the controlled release of bioactive molecules,
and for the encapsulation of living cells. For these applications, it is often required that the hydrogels
degrade under physiological conditions, i.e., the originally three-dimensional structures have to
disintegrate preferably in harmless products to ensure a good biocompatibility of the biomaterial.
Recently, much attention has been paid to chitosan (CTS) because of its advantageous
biological properties such as biodegradability, biocompatibility and non-toxicity as well as its
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physicochemical properties [43]. Thus, CTS and its derivatives have been used as an absorption
enhancer [44], drug carrier [45,46], mucoadhesive and permeation enhancing polymer in formulations
for buccal/sublingual, nasal, gastrointestinal, vaginal, colonic drug delivery [47] and for gene
delivery [48].
Chitosan has been found to be degradable by the colon microflora. Taking advantage of this
property, CTS has turned out to be a useful material to guarantee the colonic drug delivery as long as
it is part of the controlled drug release systems [49]. These materials can adhere tightly to mucosal
surfaces such as gastrointestinal tract (GIT) walls and transiently opening the tight junction between
epithelial cells, enhancing drug absorption across intestinal epithelial cells without injuring them [50].
Thus, for example, sustained intestinal delivery of drugs such as 5-fluorouracil and insulin seems
to be a feasible alternative to injection therapy [51]. In addition, the bioadhesiveness property of
chitosan-based DDS has made its formulations useful as local drug-depots [52]. The above-mentioned
properties make CTS an ideal polymer for colon-specific drug release and it was the biocompatible
polymer chosen in the present work.
In general terms, polymeric network formation can be accomplished either by non-covalent
physical associations, such as secondary forces (hydrogen, ionic, or hydrophobic bonds) and physical
entanglements, or by covalent cross-links. To form stabilizing linkages in chitosan-based materials,
the amine moieties present in their structure allow the linkage between the chains through selected
cross-linkers to prevent gel dissociation.
In a previous work, we have carried out the synthesis of micro-structured biomaterials based
on ionically cross-linked CTS for their applications as biocompatible carriers of drugs and bioactive
compounds. The influence of the dispersion composition on its rheological properties was evaluated.
The release profiles of a model drug, diclofenac sodium (DCNa) as well as their relationships with
polymer concentration, drug loading and degree of cross-linking were established [53]. Based on this
study, we have carried out the preparation of CTS-based bioadhesive hydrogels with RES-loaded
NP embedded into their structure. In this case, part of the distilled water necessary for the hydrogel
formation has been replaced by an optimized RES-loaded NP suspension.
The spreadability of the systems as well as their morphologies and thermogravimetric analyses of
the freeze-dried samples were investigated. Surprisingly, the macroscopic properties of the composites
were similar to those without the inclusion of the nanoparticles. Table 4 displays some relevant data
from the systems studied.
Table 4. Comparison of spreadability and TGA (Thermogravimetric Analysis) data of resveratrol-
loaded hydrogel-NP composites (with cross-linked NP and non-cross-linked NP.
Sample
Spreadability (diameter, cm)a TGAb
t 1 min t 30 min ∆diameter (%) ◦Td (◦C) maxTd (◦C) ∆W (%)
Mass Residue
at 650 ◦C (%)
CTS - 110 72/297 9/58 30
Xr-CTS-RES 5 8.2 64 98 62/281 24/43 32
Non-Xr-CTS-RES 5.6 8.9 59 99 111/281 24/42 32
a: Spreadability measured in cm; ∆ diameter = change of diameter (in percentage) after 30 min; b: Onset
decomposition temperature corresponding to 10% of weight loss (◦Td); maximum rate decomposition temperatures
(maxTd) and weight loss at the respective decomposition step [∆W(%)] determined by TGA.
The mechanical properties of formulations designed for GIT administration are fundamental
in composite performance. The spreadability of the product is one of them and contributes to the
final clinical efficacy of the product [54]. On the other hand, the composites need the displaying
mucoadhesion properties to act as an RES depot in the GIT. Mucoadhesion is controlled by the affinity
of the material for the mucin glycoproteins of the mucus and CTS has demonstrated the exhibition
of excellent mucoadhesive properties due to its amine and hydroxyl groups, which are involved
in its prolonged residence time in the gastrointestinal tract [49]. The composite formulated in the
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present work displayed excellent spreadability properties as expected, which ensure the satisfactory
application on the damaged tissue. From data obtained in the current and previous works, it can be
concluded that the higher the CTS concentration in the formulations, the more structured hydrogels
are obtained, and the lower the spreadibility found.
A thermogravimetric study of the commercial CTS and the two freeze-dried CTS-NP conjugates
was conducted in order to reveal the variations in thermal degradability between the starting material
and the composites. Their traces are superimposed in Figure 4. For illustrative purposes, the curves
that represent the derivative weight loss vs. temperature are also included.
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2.3. Resveratrol Release Studies
The last part of the present ork focused on evaluating the release of RES from the NPs and
the CTS-NP composites in simulated colonic environments. Due to the highly-structured hydrogel
scaffolds, the mechanisms of drug release from them are markedly different from those of other DDSs
such as micelles and dendrimers. Previous odeling studies predicted that the release of an active
agent from a hydrogel is determined by the rate-limiting step of the process and, therefore, categorized
as diffusion-controlled, swelling-controlled, or chemically-controlled, being the former the primary
mechanism that governs the release of drugs from hydrogels [49].
Both the NPs and the CTS-NPs composites were im ersed in a simulated colonic environment at
37 ◦C and the drug release was evaluated by UV-Vis measurements at 307 nm. The cumulative RES
release profiles of NPs and CTS-NPs composites are shown in Figure 6A,B, respectively.
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The percentages of drug release were determined using Equation (1):
Cumulative RES release (%) =
mentrapped(0) − mresidual(t)
mentrapped(0)
× 100 (1)
where mentrapped (0) is the weight of initial entrapped RES into the NPs; mresidual (t) is the weight of
residual RES at time “t” into the nano-microcarriers.
For these trials, the use of normalized data was chosen in order to compare the capacity of the
systems studied to retain or not the drug into the NPs (non- or cross-linked) on their own (Figure 6A)
or immersed into a CTS network (Figure 6B).
The most significant fact observed was the similar behavior of both NPs studied, with a positive
sustained release of RES over time. When the CTS-NPs composites were studied, it was be taken into
account that cross-linkages in hydrogels could sufficiently restrain the hydrogel 3D-networks and the
water flow within the systems. On the other hand, physical associations would rise to reversible bonds,
labile over time and with definitive effects on the drug release kinetics of hydrogel-based DDS.
As expected, once the RES reservoir was immersed into a CTS network, a substantial decrement in
RES release rates was observed, and hence most of the drug remained in the composite (final cumulative
release (%) after 48 h: 29–34%), highlighting the marked influence of network environments on the
drug release rates. These facts support the hypothesis that there are significant benefits associated with
the design of drug depot systems based on nano-microstructured CTS biomaterials.
3. Materials and Methods
3.1. Materials
Resveratrol was provided by Segura’s Center of Edaphology and Applied Biology (CEBAS-CSIC)
(Murcia, Spain). For the present work, a CTS sample (deacetylation degree = 75%) from Sigma-Aldrich
(Saint Louis, MO, USA) has been chosen. CTS molecular weight (Mv) was determined by viscometric
analysis using an Anton Paar AMVn automated microviscometer. By means of the Mark–Houwink
equation ([η] = 3.385 dL/g), Mv was found to be 299 kDa [57]. The other chemicals used in the current
work were purchased from Sigma-Aldrich and used as received. The 1 kDa cut-off mini-dialysis tubes
used in the present work were purchased from GE Healthcare (Wauwatosa, WI, USA).
3.2. General Methods
Ultraviolet-visible (UV-Vis) measurements were carried out using a Shimadzu UV-2102 PC
UV–visible spectrophotometer (Kyoto, Japan). The data were the result of, at least, three measurements.
The morphologies of the hydrogels were observed by field emission scanning electron microscopy.
Before SEM observations, the samples scaffold were directly frozen at –20 ◦C for 3 h, then at –80 ◦C
for 24 h. They were then lyophilized by freeze drying for 24 h. Finally, the dry hydrogel was fixed
on aluminum stubs, coated with a thickness of about 10 nm of platinum-iridium (Pt-Ir), and imaged
by scanning electron microscopy using a field emission FEI TENEO microscope (Hillsboro, OR, USA)
operating at 5 kV at the General Research Services of the University of Seville (CITIUS).
By using of a Malvern Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) at 25 ◦C,
the morphological parameters of the nanoparticles, i.e., the size distribution (polydispersity index,
PdI) and the average diameter (Dh) were estimated by dynamic light scattering (DLS). Data for each
sample were the result of the average from at least three measurements performed with a scattering
angle of 173 ◦ to the incident beam, and figures were analyzed by means of a CONTIN algorithm.
The chosen samples were examined by thermogravimetric analysis (TGA), and the decomposition
temperatures of the different samples could be observed. Thermogravimetric analyzer was TA
Instruments Q-600 SDT (New Castle, DE, USA). Platinum pans containing approximately 5 mg of each
sample were used. Trials were conducted under inert atmosphere (nitrogen, heating rate = 10 ◦C/min),
from 0 ◦C to 700 ◦C. The spreadability of the nanostructured hydrogels was attained by measuring the
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extension area (diameter in cm, after 1 min and 30 min) of the sample when it is situated between two
glass plates (20 cm × 20 cm) and exposed to a constant weight.
3.3. Micelle Formation
The nanoparticles were prepared from a synthesized block-copolymer with the molar composition
poly[(DMAEMA31%-HEMA19%)-block-(DEAEMA45%-FMA5%)] (Mn = 34,700; Mw = 45,100; Mw/Mn
= 1.3) [58] and some of the nanoparticles were cross-linked by Diels–Alder reaction, using
1,8-dimaleimide-3,6-dioxaoctane (DMDOO) as a cross-linker [59].
3.4. Preparation of Resveratrol-Loaded NPs
The general loading procedure was conducted as follows: the selected micellar dispersion was
introduced into a mini-dialysis tube (1 kDa cut-off, GE Healthcare). The latter was placed into a
sealed tube containing a freshly prepared aqueous-based RES solution (1:4 v/v DMSO-water) at a
predetermined RES/polymer ratio and gently stirred for 24 h at 25, 32 or 39 ◦C. To determine the
encapsulation efficiency in the loading processes, the remaining RES concentrations were measured at
predetermined times by UV spectroscopy at 307 nm.
3.5. Experimental Design to Study the Effect of Loading Conditions on Resveratrol Encapsulation
The encapsulation studies of resveratrol by the freshly prepared non- and core cross-linked NPs
were conducted by means of UV spectroscopy varying several experimental parameters such as
RES/polymer ratio and temperature. The RES-loaded NPs with the optimized EE were also studied
by DLS. These systems were the RES-loaded NP of choice to be embedded into CTS-based hydrogels.
In order to obtain optimized conditions for the loading step, a Box–Behnken experimental design
(CSS Statistica, StatSoft Inc., Tulsa, OK, USA) was used to evaluate the significance of the independent
variables (temperature and resveratrol/polymer ratio), as well as the interactions among them in
the non- and core cross-linked NPs. This experimental design [60,61] enabled the construction of
second-order polynomials for each independent variable and the identification of statistical significance
in the variables. For two variables, 10 experimental points are established.
Independent variables were normalized by using Equation (2):
Xn =
X − Xmed
(Xmax − Xmin) / 2 (2)
where Xn is the normalized value of independent variables; X is the absolute experimental value of
the variable concerned; Xmed is the mean of all fixed values for the variable in question; and Xmax and
Xmin are the maximum and minimum values of the variable, respectively.
To study the influence of RES/polymer ratio and temperature in the systems, 20 RES-loaded NP
systems, 10 of them named NonXr-RES/POLx-Ty and the other 10 systems named Xr-RES/POLx-Ty
were prepared from non cross-linked NPs and cross-linked NPs, respectively. The final polymer
concentration was 0.1 mg/mL, the final targeted RES/polymer ratios were 0.25, 0.50 and 0.75, and the
loading temperatures were 25 ◦C, 32 ◦C and 39 ◦C.
Encapsulation efficiency of RES embedded into the nanoparticles were calculated according to
Equation (3):
EE =
mass o f RES loaded into NP
mass o f RES at t0 in the incubation tube
× 100 (3)
3.6. Preparation of Nanostructured Chitosan-Based Hydrogels with Resveratrol-Loaded Nanoparticles
Two systems were prepared with CTS of molecular weight 199 kDa, (based on viscosity values)
and deacetylation degree of 75%, one of them with the incorporation of non-cross-linked RES-loaded
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NPs and the other with the cross-linked counterpart. The final CTS concentration was set at 4% w/w
and the degree of crosslinking 10%.
Firstly, the NPs (cross-linked and non-cross-linked) were loaded with RES under the optimized
conditions disclosed in the experimental design described above: RES/polymer ratio: 0.75; temperature:
39 ◦C, loading time: 24 h. Secondly, the hydrogel preparation was conducted similarly to the procedure
recently described by us [53] that can be summarized as follows: CTS (0.4 g, 1.74 mmol of free amine
groups) was charged in a round-bottom flask provided with a stirrer bar; then, an aqueous solution
of tricarballylic acid (1.02 mL, 10 mg/mL, 0.05 mmol), a solution of acetic acid (0.1 mL, 52% w/v), a
dispersion of resveratrol-loaded NPs (5.5 mL, RES 0.9375 mg/mL) and double-distilled water [up to
a final weight of 10 g (final polymer concentration: 4% w/w)] were added in sequence. The mixture
was stirred to homogenization at 40 ◦C during 1.5 h. The solution was cooled at 25 ◦C and the stirring
proceeded overnight at 25 ◦C.
3.7. Release Studies
In order to check the release of the RES-loaded NPs, two samples, cross-linked and non-
cross-linked NPs, were prepared under optimum uploading conditions (RES/polymer ratio: 0.75;
temperature: 39 ◦C, loading time: 24 h). Next, the RES released during the trials were determined by
UV-Vis spectroscopy at 307 nm, similarly to the general procedure described above for the loading
assays. In these cases, a mini-dialysis tube containing the NP dispersion was immersed into simulated
colon fluids (pH = 6.0 ± 0.25 [62]) and the temperature was set at 37 ◦C.
When the release of RES from hydrogel-NP composites was conducted, the selected RES-loaded
composite was transferred to a dialysis bag (molecular weight cut-off: 8000–14,000 Da), then
immersed in simulated colon fluids and gently stirred at 37 ◦C in a shaker incubator (Heidolph
Unimax1010-Heidolph Inkubator 1000, Schwabach, Alemania). At pre-designed time intervals, aliquots
were taken from the release medium and the amount of RES released was determined by UV–Vis
spectroscopy at 307 nm. RES release experiments were performed in triplicate.
4. Conclusions
Resveratrol (RES), a natural occurring multi-therapeutic drug, has demonstrated its capability of
reducing inflammation associated with gastrointestinal tract pathologies. Our efforts have focused on
the design and development of new smart micro- and nano-structured gel-like drug delivery systems
as colon-specific RES depots.
The drug was successfully encapsulated in freshly-prepared biocompatible non- and cross-linked
NPs, which, in turn, were integrated into a chitosan gel matrix. The influence of two
parameters, the temperature and the drug/polymer ratio, on the encapsulation efficiency (EE) in
the non-cross-linked NP was compared with that found on the cross-linked systems, discovering that
the temperature exerted the prevailing influence. RES-loaded CTS-NP formulations were efficiently
prepared by immersing RES-loaded NPs in 4% CTS suspensions with subsequent gelation by ionic
cross-linking. The study of the two drug-depots by TGA and SEM disclosed porous scaffolds with
great similarities in their thermal stability patterns.
RES release from NPs was next investigated finding that non- and cross-linked NPs behaved
similarly over the period of time studied (48 h). While they displayed a sustained RES release (final
cumulative drug release after 48 h: 79–81%), the RES-loaded CTS-NP hydrogels, prepared at 37 ◦C,
4% CTS and 10% of cross-linking, showed a marked reduction in RES release rates (reductions in RES
release after 48 h: 57% and 64%).
Therefore, it has been proved that, in the prepared RES depots, the chitosan network is responsible
for substantially reducing the release rate of drugs, conforming such systems into a versatile tool that
could potentially endow therapeutic benefits in the treatment of IBD through prolonged retention
and delivery.
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RES Resveratrol
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DDS Drug Delivery Systems
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